Novartis has recently announced the results of their Phase II BYLieve trial, which is investigating Piqray® (alpelisib) as a treatment for hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-)…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
